Druggable targets in pediatric neurocutaneous melanocytosis: Molecular and drug sensitivity studies in xenograft and ex vivo tumor cell culture to identify agents for therapy

Neuro-Oncology

Volumn 17, Issue 6, 2015, Pages 822-831

  Ruan, Yibing ^a   Kovalchuk, Anna ^b   Jayanthan, Aarthi ^a   Lun, Xueqing ^a   Nagashima, Yoji ^c   Kovalchuk, Olga ^b   Wright, James R ^d   Pinto, Alfredo ^d   Kirton, Adam ^d   Anderson, Ronald ^a   Narendran, Aru ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF LETHBRIDGE   (Canada)

^c YOKOHAMA CITY UNIVERSITY   (Japan)

^d ALBERTA CHILDREN'S HOSPITAL   (Canada)

Author keywords

Molecular profiling; Neurocutaneous melanocytosis; Targeted therapy

Indexed keywords

1 [4 [(5 CYCLOPROPYL 1H PYRAZOL 3 YL)AMINO]PYRROLO[2,1 F][1,2,4]TRIAZIN 2 YL] N (6 FLUORO 3 PYRIDINYL) 2 METHYL 2 PYRROLIDINECARBOXAMIDE; 2 (4 AMINO 1 ISOPROPYL 1H PYRAZOLO[3,4 D]PYRIMIDIN 3 YL) 1H INDOL 5 OL; 2 AMINO 8 [4 (2 HYDROXYETHOXY)CYCLOHEXYL] 6 (6 METHOXY 3 PYRIDINYL) 4 METHYLPYRIDO[2,3 D]PYRIMIDIN 7(8H) ONE; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; APITOLISIB; BINIMETINIB; LINSITINIB; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; NAVITOCLAX; NVP AEW 541; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PIK 75; PIMASERTIB; RAPAMYCIN; RDEA 119; SAPANISERTIB; SELUMETINIB; TRAMETINIB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; GUANOSINE TRIPHOSPHATASE; MEMBRANE PROTEIN; MOLECULAR LIBRARY; NRAS PROTEIN, HUMAN; TRANSCRIPTOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CENTRAL NERVOUS SYSTEM TUMOR; CHILDHOOD CANCER; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG TARGETING; ENZYME INHIBITION; EX VIVO STUDY; FEMALE; GENE EXPRESSION; GENE MUTATION; GENETIC HETEROGENEITY; HUMAN; HUMAN CELL; MELANOCYTOSIS; MOLECULAR GENETICS; MOLECULARLY TARGETED THERAPY; MOUSE; NEUROCUTANEOUS MELANOCYTOSIS; NONHUMAN; ONCOGENE N RAS; TUMOR CELL CULTURE; TUMOR XENOGRAFT; ADMINISTRATION AND DOSAGE; ANIMAL; DRUG EFFECTS; DRUG SCREENING; GENETICS; MALE; MELANOSIS; MOLECULAR LIBRARY; MUTATION; NEUROCUTANEOUS SYNDROMES; NUDE MOUSE; PATHOLOGY; PRESCHOOL CHILD; PROCEDURES; SIGNAL TRANSDUCTION; THERAPEUTIC USE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CHILD, PRESCHOOL; GTP PHOSPHOHYDROLASES; HETEROGRAFTS; HUMANS; MALE; MELANOSIS; MEMBRANE PROTEINS; MICE; MICE, NUDE; MUTATION; NEUROCUTANEOUS SYNDROMES; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES; TRANSCRIPTOME; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84937519718     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou310     Document Type: Article

References (27)

1. Kadonaga JN, Frieden IJ. Neurocutaneous melanosis: definition and review of the literature. J Am Acad Dermatol. 1991;(5 Pt 1):24:747-755.
2. Shah KN. The risk of melanoma and neurocutaneous melanosis associated with congenital melanocytic nevi. Semin Cutan Med Surg. 2010;29(3):159-164.
3. Agero AL, Benvenuto-Andrade C, Dusza SW, et al. Asymptomatic neurocutaneous melanocytosis in patients with large congenital melanocytic nevi: a study of cases from an Internet-based registry. J Am Acad Dermatol. 2005;53(6):959-965.
4. Arneja JS, Gosain AK. Giant congenital melanocytic nevi. Plast Reconstr Surg. 2009;124(1 Suppl):1e-13e.
5. Cramer SF. The melanocytic differentiation pathway in congenital melanocytic nevi: theoretical considerations. Pediatr Pathol. 1988;8(3):253-265.
6. Kinsler VA, Thomas AC, Ishida M, et al. Multiple congenital melanocytic nevi and neurocutaneous melanosis are caused by postzygotic mutations in codon 61 of NRAS. J Invest Dermatol. 2013;133(9):2229-2236.
7. Ball NJ, Yohn JJ, Morelli JG, et al. Ras mutations in human melanoma: a marker of malignant progression. J Invest Dermatol. 1994;102(3):285-290.
8. Charbel C, Fontaine RH, Malouf GG, et al. NRAS mutation is the sole recurrent somatic mutation in large congenital melanocytic nevi. J Invest Dermatol. 2014;134(4):1067-1074.
9. Nagashima Y, Miyagi Y, Aoki I, et al. Establishment and characterization of a malignant melanoma cell line (YP-MEL) derived from a patient with neurocutaneous melanosis. Pathol Res Pract. 1994;190(2):178-185.
10. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44-57.
11. Singh A, Lun X, Jayanthan A, et al. Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): favorable activity of targeting. Mol Oncol. 2013;7(3):497-512.
12. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70(2):440-446.
13. Alajez NM, Shi W, Wong D, et al. Lin28b promotes head and neck cancer progression via modulation of the insulin-like growth factor survival pathway. Oncotarget. 2012;3(12):1641-1652.
14. Polesskaya A, Cuvellier S, Naguibneva I, et al. Lin-28 binds IGF-2 mRNA and participates in skeletal myogenesis by increasing translation efficiency. Genes Dev. 2007;21(9):1125-1138.
15. Pedersen M, Kusters-Vandevelde HV, Viros A, et al. Primary melanoma of the CNS in children is driven by congenital expression of oncogenic NRAS in melanocytes. Cancer Discov. 2013;3(4):458-469.
16. Kusters-Vandevelde HV, Willemsen AE, Groenen PJ, et al. Experimental treatment of NRAS-mutated neurocutaneous melanocytosis with MEK162, a MEK-inhibitor. Acta Neuropathol Commun. 2014;2:41.
17. Molhoek KR, Shada AL, Smolkin M, et al. Comprehensive analysis of receptor tyrosine kinase activation in human melanomas reveals autocrine signaling through IGF-1R. Melanoma Res. 2011;21(4):274-284.
18. Hilmi C, Larribere L, Giuliano S, et al. IGF1 promotes resistance to apoptosis in melanoma cells through an increased expression of BCL2, BCL-X(L), and survivin. J Invest Dermatol. 2008;128(6):1499-1505.
19. Neudauer CL, McCarthy JB. Insulin-like growth factor I-stimulated melanoma cell migration requires phosphoinositide 3-kinase but not extracellular-regulated kinase activation. Exp Cell Res. 2003;286(1):128-137.
20. Grimberg A, Cohen P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol. 2000;183(1):1-9.
21. Kazerounian S, Yee KO, Lawler J. Thrombospondins in cancer. Cell Mol Life Sci. 2008;65(5):700-712.
22. Lindner DJ, Wu Y, Haney R, et al. Thrombospondin-1 expression in melanoma is blocked by methylation and targeted reversal by 5-Aza-deoxycytidine suppresses angiogenesis. Matrix Biol. 2013;32(2):123-132.
23. Satelli A, Rao US. Galectin-1 is silenced by promoter hypermethylation and its re-expression induces apoptosis in human colorectal cancer cells. Cancer Lett. 2011;301(1):38-46.
24. Anand N, Murthy S, Amann G, et al. Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer. Nat Genet. 2002;31(3):301-305.
25. Sorolla A, Yeramian A, Dolcet X, et al. Effect of proteasome inhibitors on proliferation and apoptosis of human cutaneous melanoma-derived cell lines. Br J Dermatol. 2008;158(3):496-504.
26. Giménez Ortiz A, Montalar Salcedo J. Heat shock proteins as targets in oncology. Clin Transl Oncol. 2010;12(3):166-173.
27. Wu X, Marmarelis ME, Hodi FS. Activity of the heat shock protein 90 inhibitor ganetespib in melanoma. PLoS One. 2013;8(2):e56134.